Merck's Biosims Business: What's For Sale And Who Will Buy It?
Merck KGaA is getting out of biosimilars – a unit that CEO Stefan Oschmann called the company's now redundant back up plan – to instead focus on its growing oncology pipeline, which includes recently acquired pipeline candidates from Vertex Pharma.
You may also be interested in...
Humira's Inevitable Decline: What's Waiting In The Wings?
There are 20 biosimilar adalimumab drugs in development – including one from Amgen that has already been approved but not yet launched. Biotechs and big pharma companies alike are lining up their candidates in preparation for when AbbVie's world-leading inflammation and immunology product Humira loses patent protection.
Birth Of A Giant: A Timeline Of Teva And Allergan's Generics Business
Graphical timeline tracks the deals that shaped the two firms from turn of the last century to the present day.
Infographic: Top 100 Pharma Companies
The Scrip 100 universe gathers FY2021 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales.